WO2014085225A1 - Pyrimidine compounds for the treatment of cancer - Google Patents

Abstract

Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.

Description

PYRJMIDI E COMPOUNDS

FOR THE TREATMENT OF CANCER

Xiaodong Wang, Weihe Zhang, Stephen V. Frye, Dmitri Kireev,

Andrew L. Mclver. and J^'ing Liu

Related A p plica lions

This application is related to PCT Applicationd Nod. PCT/US 20.11/036215 filed May 12, 2011 (Attorney Docke No. 5470-549WO); PCT/US2012/0582:98 filed Oct 01, 2012 (Attorney Docket No. S470-610WO); and PCT/US2013/042033, tiled May 21 , 2013 (Attorney Docket No. 5470-627 WO).

Field of the Invention

The present invention, concerns compounds, compositions and methods for the treatment of cancer.

Background of the. iBveatioi.

Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children and common varieties are cured by chemotherapy in 75%~85% of the cases. Collectively the less common T ceil and rare B ceil subsets represent less than 2000 cases yearly and thus can be classified as a rare disease; these subsets have a poorer prognosis. Unfortunately with either subset, resistance to and relapse from therapy is a major cause of pediatric cancer death. In addition. ALL chemotherapies can cause late complications that are increasingly recognized in pediatric survivor populations. In fact, in pediatric cancer survivors, the incidence of severe !ate effects (neurocognitive sequelae, auditory complications, cardiovascular dysfunction, gastrointestinal/hepatic dysfunction, growth delay, secondary malignancies, and infertility) directly related to therapy is approximately 25%. A better understanding of therapeutic resistance and its reversal could not only help those who relapse but may help lower the dose of chemotherapy needed in ALL patients thus reducing long-term toxicity for future survivors. Summary of thejDyention

A first aspect of the invention is active compounds of Formula 1 or ii:

wherein:

Ring A is a 5- or 6-raembered heteroaryl group such as pyridyl, pyrimidyl. thiazol, furanyl, pyridazinyl, pyrazinyl, imidazol, etc.. The dashed line is an optional double bond, X is N or O. Y is C. S or N and ca move on the ring.

R is ~R^JR°, where R^J is a covaient bond or CI to C3 aikyl or a linker group (for example, sulfonamide, amide, etc.) and R⁶ is cycloalkyl. heterocycloaikyl, aryl, heteroaryl aikylcycloalkyl, alkylbeterocycloalkyl, alkylaryl, aikylheteroaryi, or alkyl, and wherein R⁶ is optionally substituted one, two or three times with independently selected polar groups:

R⁴ is -R⁷R^S, where R⁷ is a covaient bond or CI to C3 alkyl and R⁸ is cycloalkyl, heterocycloaikyl, aryl, heteroaryl or alkyl, and wherein R⁸ is optionally substituted one, two or three times with independently selected polar groups;

R³ is selected from the group consisting of H, alkyl, arylalkyl; cycioalkyialkyi, heterocyeloaikylalkyl, heteroaryalkyl, and aikoxyalkyl, each of which is optionally substituted one, two or three times with independently selected polar groups;

or ^" and R^" together form a linking group;

R⁴ is H, loweralkyl, halo, or loweraikox'v;

or a pharmaceutically acceptable salt thereof.

A further aspect of the invention is an active compound as described herein in a pharmaceutically acceptable carrier.

A further aspect of the invention is a method of treating cancer in a subject, in need thereof, comprising administering said subject an active compound as described herein in an amount effective to treat the cancer.

A fuller aspect of the invention is an active compound as described herein for use in treating cancer, and/or for the preparation of a medicament for the treatment of cancer. Detailed Description of Prefer ed Emboidiments

"Alkyl" as used herein alone or as pariof another group, refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alky! include, but. are not limited, to, methyl, ethyl, n-propyl, iso-propy!, n-butyl, sec-butyl, iso-b tyl, tert-butyl, n-pentyl, isopentyl, neopentyL n-hexyl, 3-methylhexyl, 2,2- dimethyl entyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like, "Lower alkyl." as used herein, is a subset of alkyl, in some embodiments preferred, and refers to a straight or branched chain hydrocarbon grou containing from 1 to 4 carbon atoms. Representative examples of lower alkyl include, but are not limited to. methyl, ethyl, n- propyi, iso-propyl, n-butyl, iso-butyl, tert-butyl, and the like. The term "alkyl" or "loweralkyi" is intended to include both substituted and unsubstituied alkyl or loweraikyl unless otherwise indicated and these groups may be substituted with groups selected from halo (e.g., haloalkyl), alkyl, haloalkyl, alkenyl, a!kynyl, cyeloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclo, heterocycloaikyf hydroxy], aikoxy (thereby creating a polyalkoxy such as polyethylene glycol), aikenyloxy, alkynyloxy, haloaikoxy, cyc!oalkoxy, cycloalkylalkyloxy, aryloxy, aryialkyioxy, heierocyclooxy, heterocycloiaikvloxy, mercapto, alkyl-S(0)_m, halo alkyl- S(0)_mj alkenyl-S(0)_m> alkynyl-S(0)_m, eyeloalkyi-5(0)_m, cycloalkyIaikyl-S(0)_m, aryi-S(Q)_m, arylalkyl-S(0)_ms. heterocyclo-S(0)_m, heterocycloalkyl- S(0)m, amino, carboxy, aikyiamino, alkenylammo, alkynylarntno, haloalkylamino, eycioalkyiamino, cycloalkyialkylamino, arylamino, aryl aikyiamino, heterocycioamino, heieroeycioalkylamino, disubstituted-axnino, acyl amino, acyloxy, ester, amide, sulfonamide, urea, aikoxyaeylaniino, aminoacyloxy, nitro or cyano where m- Q, 1 , 2 or 3.

"Alkenyl" as used herein alone or as part of another group, refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms for in Ioweralkeny 1 1 to 4 carbon atoms) which include 1 to 4 double bonds in the normal chain. Representative examples of alkenyl include, but are not limited to, vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4- pentenyl, 3-pentenyl, 2-hexenyl, 3-bexenyl, 2,4-heptadiene, and the like. The term "alkenyl" or "loweralkenyl" is intended to include both substituted and unsubstituied alkenyl or loweralkenyl unless otherwise indicated and these groups may be substituted with groups as described in connection with alkyl and loweralkyi above.

"Alkynyl" as used herein alone or as part o another group, refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms (or in loweralkynyl 1 to 4 carbon atoms) which include 1 triple bond in the normal chain. Representative examples of alkynyl include, but are not limited to, 2-propynyl, 3-butynyi, 2- buiynyl, 4-pentynyl. 3- pentynyi, and the like. The term "alkynyl" or "ioweralkynyl" is intended to include both substituted and unsubstitvtted alkynyl or Ioweralkynyl unless otherwise indicated and these groups may be substituted with the same groups as set forth in connection with alkyl and ioweraikyl above.

"Cycloalkyl" as used herein alone or as part of another group, refers to a saturated or partially unsaturated cyclic hydrocarbon group containing from 3, 4 or 5 to 6. 7 or 8 carbons (which carbons may be replaced in heterocyclic group as discussed below). Representative examples of cycloalkyl include, cyclopropyl, cyclobutyl, cyclopenty!, cyelohexyl, eyeloheptyl. and cyclooctyl. These rings may be optionally substituted with additional substituents as described herein such as halo or Ioweralkyl The term "cycloalkyl" is generic and intended to include heterocyclic groups as discussed below unless specified otherwise.

"Heterocyclic group'¹ or "heterocycio" as used herein alone or as part of another group,, refers to an aliphatic (e.g., fully or partially saturated heterocyclo) or aromatic (e.g., heteroaryt) monocyclic- or a bicyclic-ring system, Monocyclic ring systems are exemplified by any 5 or 6 membered ring containing 1 , 2, 3, or 4 heteroatoms independently selected from oxygen, nitrogen and sulfur. The 5 membered ring has from 0-2 double bonds and the 6 membered ring has from 0-3 double bonds. Representative examples of monocyclic ring systems include, but are not limited to, azetidine. azepine, aziridine, diazepine, 1 ,3-dioxolane, dioxane, dithiane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazoline, isothiazo!idine, isoxazole, isoxazoline, isoxazolidine, morphoiine, oxadiazole, oxadiazoline, oxadiazoiidme, oxazole, oxazoline, oxazolidine, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazolone, pyrazolidine, pyridine, pyrimidine. pyridazine, pyrrole, pyrroline, pyrrolidine, tetrahydro furan, tetrahydrothiophene, tetrazine, tetrazole, thiadiazole, thiadiazoline, thiadiazolidine, thiazole, thiazoline, thiazolidine, ihiophene, thiomorpholine, thiomorpholine sulfone, thiopyran, triazine, triazole, tritbiane, and the like, Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system as defined herein. Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazole, benzoihiazole, benzothiadiazoie, benzothiophene, benzoxadiazole, benzoxazole, benzofuran, benzopyran, benzothiopyran. benzodioxine, 1,3- benzodioxo!e, cinnoline. indazole, indole, indoline, indolizine, naphthyridine, isobenzofuran, isobenzothiophene, isoindole, isoindoline, isoquinoline, phthalazine, purine, pyranopyridine, quinoline, qinnolizine, quinoxaiine, quinazoline, tetrahydroisoquinoline, tetrahydroquinoline, thiopyranopyridine, and the like. These rings include quaternized derivatives thereof and may be optionally substituted with groups selected from halo, alkyl, haloaikyi, alkenyl, alkynyl, cycloaikyl, cycloalkyialkyl, aryl, arylalkyl, heterocycio, heterocycioalkyl, hydroxy!, alkoxy, alkenyloxy, aikynyioxy, haloalkoxy, eycloalkoxy, cyeioalkylalkyloxy, aryloxy, arylalkyloxy, heterocyclooxy, heterocyclolalkyloxy, mercapto, alkyl~S(0)_m, haioalkyl~S(0)_m, alkenyl- S(0)_m, alkynyl -S(0)_m, cycloalkyi~S(Q)_mj cycloalkylalkyl-S(0)_m, aryl-S(0)_1Tl! arylalkyl - S(0)_m, heterocyclo-S(0)_ms heterocycloalkyl-S(0)_m, amino, alkylamino, alkenylamino, alkynyl amino, haloalkylamino, cycloalkylamino, cycioaikylalkylamino, arylamino, arylalkylamino, heterocycloamino. heterocycloalkyiamino, disubstituted-amino, acylaraino, acyloxy, ester, amide, sulfonamide, urea, alkoxyacylammo, ammoacyloxy, nitro or cyano where m - 0, 1 , 2 or 3.

"Aryl" as used herein alone or as part of another group, refers to a monocyclic carbocyclic ring system or a bicyclic carbocyclic fused ring system having one or more aromatic rings. Representative examples of aryl include, azuienyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like. The term "aryl" is intended to include both substituted and unsubstituted aryl unless otherwise indicated and these groups may be substituted with the same groups as set forth in connection with alkyl and loweralkyl above.

"Arylalkyl" as used herein alone or as part of another group, refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, benzyl, 2- phenylethyl, 3-phenylpropyl, 2-naphth-2-ylet;hyl, and the like.

"Heteroaryi" as used herein is as described in connection with heterocycio above,

"Alkoxy" as used herein alone or as part of another group, refers to an alkyl or loweralkyl group, as defined herein (and thus including substituted versions such as polyalkoxy), appended to the parent molecular moiety through an oxy group, -0-. Representative examples of alkoxy include, but are not limited, to, methoxy, ethoxy, pro poxy, 2-propoxy, butoxy, iert-butoxy, pentyioxy, hexyloxy and the like.

"Halo" as used herein refers to any suitable halogen, including -F, -CI, -Br, and -I.

"Mercapto" as used herein refers to an. -SB group,

"Azido" as used herein refers to an -N3 group.

"Cyano" as used herein refers to a -CN group.

"Formyi" as used herein refers to a -C(0)H group. "Carboxylic acid" as used herein refers to a -C(0)GH group.

"Hydroxy 1" as used herein refers to an -OH group.

" itro" as used herein refers to an -NO_?, group.

"Acyl" as used herein alone or as part of another group refers to a -C(0)R radical, where R is any suitable substituent such as aryl. aikyl, aikenyi, alkynyi, cycloaikyl or other suitable substituent as described herein.

"Alkylthio" as used herein alone or as part of another group, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio. tert-butylihio, hexylihio, and the like.

"Amino" as used herein means the radical ~-N¾.

"Alkylaniino" as used herein alone or as part of another group means the radical - NHR, where R is an alkyl group.

"Arylalkylamino" as used herein alone or as part of another group means the radical ~ NHR, where R is an aryl alkyl group.

"Disubstituted-amino" as used herein alone or as part of another group means the radical -NR_sR_b, where R_a and R_lt are independently selected from the groups alkyl, haloalkyl, aikenyi, alkynyi. cycloaikyl, cycloalkyialkyl, aryl, arylalkyl, heterocyclo, heterocycloaikyl.

"Acylamino" as used herein alone or as part of another group means the radical -· NR_aRb, where R_a is an acyl group as defined herein and R is selected from the groups hydrogen, alkyl, haloalkyl, aikenyi, alkynyi, cycloaikyl, cycloalkyialkyl, aryl, arylalkyl, heterocyclo , hetero c c 1 o alkyl .

"Aeyioxy" as used herein alone or as pari of another group means the radical -OR, where R is an acyl group as defined herein.

"Ester" as used herein alone or as part of another group refers to a -C(0)OR radical, where R is any suitable substituent such as alkyl, cycloaikyl, aikenyi, alkynyi or aryl.

"Amide" as used herein alone or as part of another group refers to a -C(0)NR_aR_b radical, where R_a and R_b are any suitable substituent such as alkyl, cycloaikyl, aikenyi, alkynyi or aryl.

"Sulfoxyl" as used herein refers to a compound of the fomiula -S(0)R. where R is any suitable substituent such as alkyl, cycloaikyl, aikenyi, alkynyi or aryl.

"Sulfonyl" as used herein refers to a compound of the fomiula -S(0)(0)R, where R is any suitable substituent such as amino, alkyl, cycloaikyl, aikenyi, alkynyi or aryl. "Sulfonate" as used herein refers to a compound of the formula -S(0)(0)OR, where R is any suitable substituent such as alkyl, cycloaikyl, alkenyl, aikynyl or aryi,

" Sulfonic acid" as used herein refers to a compound of the formula -S(0)(0)OH.

"Sulfonamide" as used herein alone or as pail of another group refers to a - S(0)2NRaRb radical, where R_a and Rb are any suitable substituent such as H, alkyl, cycloaikyl, alkenyl, aikynyl or aryL

"Urea" as used herein alone or as part of another group refers to an - (R_c)C(0) R_aR_b radical where R_a, R_b and _e are any suitable substituent such as H, alkyl, cycloaikyl, alkenyl, aikynyl or aryL

"Alkoxyacylamino" as used herein alone or as part of another group refers to an - N(Ra)C(0)ORb radical, where R_a, R_b are any suitable substituent such as H, alkyl, cycloaikyl, alkenyl, aikynyl or aryL

"Ammoacyioxy" as used herein alone or as part of another group refers to an - OC(0)NR_aRb radical, where R_a and Rb are any suitable substituent such as H, alkyl, cycloaikyl, alkenyl, aikynyl or aryL

"Polar group" as used herein refers to a group wherein the nuclei of the atoms co vaiently bound to each other td form the group do not share the electrons of the eovalent bond (s) joining them equally; that is the electron cloud is denser about one atom than another. This results in one end of the eovalent bond(s) being relatively negative and the other end relatively positive; i.e., there is a negative pole and a positive pole. Examples of polar groups include, without limitations, halo, hydroxy, alkoxy, carboxy, nitro, cya.no, amino (primary, secondary and tertiary), amido, ureido, sulfonamido, sulfinyl, suifhydryl silyl, S- sulfonamido. N-sulfonamido, C-carboxy, O-carboxy, C-amido. N-amido, sulfonyl, N-ferr- butoxycarbonyl (or "r-BOC") groups, phosphono, morpholino, piperazinyL tetrazolo, and the like. See, e.g., U.S. Pat. No. 6,878,733, as well as alcohol, thiol, polyethylene glycol, polyol (including sugar, aminosugar, uronic acid), sulfonamide, carboxamide, hydrazide, N- hydroxycarboxamide, urea, metal chelates (including macrocyclic ligand or crown ether metal chelates). The polar group can be an ionic group.

"Ionic group" as used herein includes anionic and cationic groups, and includes groups (sometimes referred to as "ionogenic" groups) that are uncharged in one form but can be easily converted to ionic groups (for example, by protonation or deprotonation in aqueous solution). Examples include but are not limited to carhoxylate, sulfonate, phosphate, amine, N-oxide, and ammonium (including quaternized heterocyclic amines such as imidazolium and pyridiniurrs) groups. See, e.g., U.S. Pat. Nos. 6,478,863; 6,800,276; and 6,896,246. Additional examples include tironic acids, carboxylic acid, sulfonic acid, amine, and moieties such as guanidinium, phosphoric acid, phosphonic acid, phosphatidyl choline, phosphonium, borate, sulfate, etc,

"Deuterium" as used herein alone or as part of another group, refers to a safe, nonradioactive relative of hydrogen. Any hydrogen in a group or substitueni described above may be replaced with deuterium to provide a "deuterated" compound, in some embodiments to modify and/or improve metabolic stability, resulting in better safety, toierability and/or efficacy.

"Linking group" or "linker group" as used herein are generally bivalent aromatic, aliphatic, or mixed aromatic and aliphatic groups. Thus linking groups include linear or branched, substituted or imsubstituted aryl, aikyl, alkylaryl, or alkylaryl alkyl linking groups, where the alkyl groups are saturated or unsaturated, and where the alkyl and aryl groups optionally containing independentl selected heteroatoms such as 1 , 2, 3 or 4 heteroatoms selected from the group consisting of N, 0, and S. In some embodiments, linking groups containing from 2 to 20 carbon atoms are preferred. Numerous examples of suitable linking groups are known, including but not limited to those described in, US Patents Nos. 8,247,572; 8,097,609: 6,624,317; 6,613,345; 6,596,935; and 6,420,377, the disclosures of which are incorporated by reference herein in their entirety.

"Treat" as used herein refers to any type of treatment that imparts a benefit to a patient afflicted with a disease, including improvement in the condition of the patient {e.g., in one or more symptoms), delay in the progression of the disease, delay in onset of the disease, etc.

"Pharmaceutically acceptable" as used herein means that the compound or composition is suitable for administration to a subject to achieve the treatments described herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.

Active compounds of the present invention may optionally be administered in conjunction with other compounds useful in the treatment of cancer. The other compounds may optionally be administered concurrently. As used herein, the word "concurrently" means sufficiently close in time to produce a combined effect (that is. concurrently may be simultaneously, or it may be two or more events occurring within a short time period before or after each other). The present invention is primarily concerned with the treatment of human subjects, but the invention may also be carried out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes. Subjects may be of any age, including infant, juvenile, adolescent, adult, and geriatric subjects.

As noted above, the present invention provides active compounds of Formula I or II:

wherein:

R^l is -R^R⁶, where R^s is a covaient bond, CI to C3 alky! or a linker group (for example, sulfonamide, amide,, etc.) and R⁶ is eycloalkyl, heterocycloalkyl, aryi, heteroaryl, alkylcycloalkyi, alkylheterocycloalkyl, al.kyl.aryl, alkyiheteroaryl or alkyl, and wherein R⁶ is optionally substituted one, two or three times with independently selected polar groups;

R^A is ~R⁷R^S, where R' is a covaient bond or CI to C3 alkyl and R⁸ is eycloalkyl, heterocycloalkyl, aryl, heteroaryl or alkyl. and wherein R is optionally substituted one, two or three times with independently selected polar groups;

R is selected from the group consisting of H, alkyl, aryla!kyk cycloalkylaikyl, heterocycioalkylaikyl, heieroaryalkyl, and alkoxyalkyl, each of which is optionally substituted one, two or three times with independently selected polar groups;

or R^" and R" together form a Unking group;

R⁴ is H, !oweralkyk halo, or loweralkoxy;

or a pharmaceutically acceptable salt thereof.

in some embodiments of the foregoing, ³ is a covaient bond; in other embodiments, R^" is CI to C3 alkylene such as -0¾~ or R is a linker group (for example, sulfonamide, amide, etc.), In some embodiments of the foregoing, ' is a covalent bond; in other embodiments,

R' is CI to C3 alkyiene such as -(.^'¾-·.

In some embodiments, R is phenyl, piperidyl, or C1-C8 alkyl, or C3 to C8 cycloaikyl, which phenyl, pipyridyl, alkyl, or cycloaikyl alkyl is unsubstituted or substituted from 1 to 3 times with sulfono, halo, amino, nitro, alkyl, alkoxy!, haloaikyl, cycloaikyl. heterocyc!oaikyl, aryl, or heteroaryl.

In some embodiments, wherein R⁸ is Cl-CS alkyl or cyclohexyl, which alkyl or cyclohexy! is unsubstituted or substituted from 1 to 3 times with hydroxy! or amino.

in some embodiments, R³ is CI-C8 alkyl, C3-C8 cycloaikyl, C4-C12 cycloalkylaikyl,

C3-C8 heteroeycioalkyh C4-C12 heterocycloaikylalkyl, C4-C12 arylalkyl, C4-C12 heteraarylaikyl, each of which is imsubstituted or substituted from, one to three times with hydroxy!, halo, or aikoxy.

In some embodiments, R⁴ is H.

Specific examples of linking groups include, but are not limited to:

where each n and m is independently 0, 1 , 2, 4, 5, or 6; and where each of the linking grou structures illustrated above may optionally be substituted, e.g., substituted one, two, or three times with independently selected polar groups.

Patic lar examples of compounds of the present invention include but are not limited to those set forth in Tables 1-7 below.

The active compounds disclosed herein can, as noted above, be provided in the form of their pharmaceutically acceptable salts. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxieologieai. effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, raaleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphihalenesulfonic acid, methanesulfonic acid, p-toiuenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; (b) salts formed from elemental anions such as chlorine, bromine, and iodine, and (c) salts derived from bases, such as ammonium salts, alkali metal, salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium, and salts with organic bases such as dicyclohexylamine and N-metliyl-D-glucamine.

Active compounds as described herein can be prepared in accordance with known procedures, or variations thereof that will be apparent to those skilled in the art.

2. Pharmaceutical . formulations.

The active compounds described above may be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (9^th Ed. 1995). In the manufacture of a pharmaceutical formulation according to the invention, the active compound (including the physiologically acceptable salts thereof) is typically admixed with, inter alia, an acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example., a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the active compound. One or more active compounds may be incorporated in the formulaiions of the invention, which may be prepared by any of the weil. known techniques of pharmacy comprising admixing the components, optionally including one or more accessory ingredients.

The formulations of the invention include those suitable for oral, rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (i.e., both skin and mucosal surfaces, including airway surfaces), transdermal administration, and intraventricular injection (injection into a ventricle of the brain, e.g., by an implanted catheter or ormnan reservoir, such as in the case of morbid obesity) and although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active compound which is being used.

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such .as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder,

Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the active compound in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia,

Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the active compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostais and solutes which render the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents. The formulations may be presented in unit\dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (iyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. For example, in one aspect of the present invention, there is provided an injectable, stable, sterile composition comprising a compound of Formula (ϊ)_> or a salt thereof, in a unit dosage form in a sealed container. The compound o salt is provided in the form of a iyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject. The unit dosage form typically comprises from about 10 rag to about 1.0 grams of the compound or salt. When the compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.

Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferably take the form, of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoUne, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable formulations comprise citrate or bis\tris buffer (pH 6) or ethanol/water and contain from O. i to 0.2M active ingredient.

Further, the present invention provides liposomal formulations of the compounds disclosed herein and salts thereof. The technology for forming liposomal suspensions is well known in the art. When the compound or salt thereof is an aqueous-soluble salt, using conventional liposome technology, the same may be incorporated into lipid vesicles. In such an instance, due to the water solubility of the compound or salt, the compound or salt will be substantially entrained within the hydrophilic center or core of the liposomes. The lipid layer employed may be of any conventional composition and may either contain cholesterol or may be cholesterol-free. When the compound or salt of interest is water-insoluble, again employing conventional liposome formation technology, the salt may be substantially entrained within the hydrophobic lipid bilayer which forms the structure of the liposome. In either instance, the liposomes which are produced may be reduced in size, as through the use of standard soni cation and homogenization techniques.

Of course, the liposomal formulations containing the compounds disclosed herein or salts thereof, may be Iyophilized to produce a lyophilizate which may be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.

Other pharmaceutical compositions may be prepared from the water-insoluble compounds disclosed herein, or salts thereof, such as aqueous base emulsions. In such an instance, the composition will contain a sufficient amount of pharmaceutically acceptable emulsifying agent to emulsify the desired amount of the compound or salt thereof. Particularly useful emulsifying agents include phosphatidyl cholines, and lecithin.

In addition to compounds of formula (I) or their salts, the pharmaceutical compositions may contain other additives, such as pB -adjusting additives. In particular, useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate. Futher, the compositions may contain microbial preservatives. Useful microbial preservatives include methylparaben, propylparaben, and benzyl alcohol. Th microbial preservative is typically employed when the formulation is placed in a vial designed for multidose use. Of course, as indicated, the pharmaceutical compositions of the present invention may be Iyophilized using techniques well known in the art,

3. Dosage aad routes o_.LadmmjstrattoB.

As noted above, the present invention provides pharmaceutical formulations comprising the active compounds (including the pharmaceutically acceptable salts thereof), in pharmaceutically acceptable carriers for oral, rectal, topical, buccal, parenteral, intramuscular, intradermal, or intravenous, and. transdermal administration.

The therapeutically effective dosage of any specific compound, the use of which is in the scope of present invention, will vary somewhat from compound to compound, and patient to patient, and will depend upon the condition of the patient and the route of delivery. As a general proposition, a dosage from about 0.1 to about 50 mg kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the active compound, including the cases where a salt is employed. Toxicity concerns at the higher level may restrict intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon, the weight of the active base, including the cases where a salt is employed. A dosage from about 10 mg/kg to about 50 mg/kg may be employed for oral administration. In some embodiments, a dosage from about 0,5 mg/kg to 5 mg/kg may be employed for intramuscular injection, In some embodiments, dosages are 1 pmoi/kg to 50 imo /kg, and more preferabl 22 μπ οΐ kg and 33 μτηοΐ/kg of the compound for intravenous or oral administration, The duration of the treatment can be once per day for a period of two to three weeks or until the condition is essentially controlled.

Active compounds may be administered as pharmaceutically acceptable prodrugs, which are those prodrugs of the active compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable risk benefit ratio, and effective for their intended use, as well as the zwitterionie forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formutae, for example, by hydrolysis in blood, A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel delivery Systems, Vol. 14 of the A.C.S. Symposium Series and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated b reference herein. See also US Patent No, 6,680,299 Examples include a prodrug that is metabolized in vivo by a subject to an active drug having an activity of active compounds as described herein, wherein the prodrug is an ester of an alcohol or carboxylic acid group, if such a group is present in the compound; an acetal or keial of an alcohol group, if such a group is present in the compound; an N-Mannich base or an inline of an amine group, if such a group is present in the compound; or a Schiff base, oxime, acetal, enol ester, oxazolidine, or thiazolidine of a carbonyl group, if such a group is present in the compound, such as described in US Patent No. 6,680,324 and US Patent No. 6,680,322.

As noted above, the active compounds described herein are usefui for the treatment of cancer. Example cancers that may be treated by the compounds and methods of the invention inciude, but are not limited to, myeioid leukemia, lymphoblastic leukemia, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine, and brain cancer.

The present invention is explained in greater detail In the following non-limiting Examples,

Examples 1.-11

General Structure I:

2,4 )ichIoro~A^4-(morpho

A solution of 2_s4-dichiorop rin idine-5~carbonyl chloride (422mg, 2,0 mmoi) in dichloromethane (10 mL) was added 4-(morpholinosulfonyl)aniline (508 nig. 2.1 mmoi) and DT.EA (387 mg, 3.0 mmoi) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, Then, water was added. The resulting mixture was extracted with Et^'OAc (3x). The combined organic layers were dried (NaaSQ*), filtered and concentrated. The residue was purified on iSCO to give the title compound as a white solid (701.2 mg, 84%). ^!H NMR (400 MHz, DMSO-r ) δ 1 1.98 - 1 1.90 (m₅ I B), 8.29 (d, J = 6.4 Hz, IH), 7.89 (d, J = 8.8 Hz, 2H), 7.69 (d, J= 8.8 Hz, 2H), 3.65 - 3.56 (m, 4H), 2.87 - 2.78 (m, 4H); MS m/z 418,30 [M+H .

A solution of 2_J4-dichloro-N-(4-(morpholinosulfonyl)p enyl)pyrimidine-5- carboxamide (700rng, 1.68 mmoi) in IPA (15 mL) was added tra«i'-4-aminoeycloliexanol (231.4 mg, 2.2 mmoi) and DIEA (387 mg_f 3,0 mmoi) at 0 °C, The resulting mixture was stirred at 0 °C for 50 min and warmed to room temperature and stirred for another 50 min. Then the solvent was removed, the residue was dissolved in a mixture of CH2CL2 and methanol (20 mL, 3:2, v/v), the suspension was filtered though a filter paper to give the title compound as a white solid (683.4 mg, 82%). Ή NMR (400 MHz, DMSO-d⁶) S 10.71 (s, IH), 8.69 (s, IH), 7.96 7.89 (m, 2H), 7.76 - 7.70 (m, 2H), 4.57 (s, IH), 3.93 - 3.81 (m, 11 1), 3.64 - 3.57 (m, 4H), 3.49 - 3.40 (m, IH), 2.88 - 2.78 (m, 4H), 1.95 - 1.86 (m, 2H), 1.85 - 1.76 (m, 2H), 1.38 ~ 1.20 (m, 4H); MS m/z 496.20 [M+Hf .

A solution of 2-chloro-4-(((lr,4r)-4-hydroxycyc.Sohexy.i)amino)-A^;r-(4- (morphoiinosulfonyl)phenyi) pyrimidine-5-carboxamide (86mg, 0.17 mmoi) in IPA (lOmL) was added butyiamine (59,6 mg, 0.81 mmoi) and DIEA (124.7 nig, 0.96 mmoi) at room temperature. The resulting mixture was stirred for 3b. at room temperature. Water was then added. The resulting mixture was extracted with EtOAc (3X). The combined organic layers were dried (NazSC^ , filtered and concentrated, The residue was purified on ISCO to give the title compound as a white solid {59.3 mg, 64%). ^!H NMR (400 MHz, CD₃OD+CDCI3) S 8.21 (s, 1H), 7.71 - 7.64 (m, 2H), 7,59 - 7.53 (in, 2H), 3.93 - 3.77 (ra, 1H), 3.74 - 3,64 (m, 4H), 3.63 - 3.58 (m, 4H), 3.56 - 3.46 (ra, 1H), 3,26 (t, J- 7.1 Hz, 2H), 2.91 - 2.81 (m, 4H), 2.05^■··^■ 1.95 (m, ^'2H), 1 .93 - 1.82 (m, 2H), 1.50 - 1.41 (m, 2H), 1.33 - 1.17 (m, 6H), 0.83 (t, J - 7.3 Hz, 3H); °C NMR (101 MHz, CD3OD+CDCI₃) S 166.8, 156,4, 143.5, 128.8, 128.6, 120.3, 120.2, 6.9.2, 66.0, 45.9, 41.0, 33.4, 31.6, 30.2, 20.0, 13.7; MS m/z 533.30 [M+Hf.

Example 2

2~(¾utylamino)-N-(4-fluorobenzyl pvrimidine carboxamide

General Procedure B:

To a solution of 2,4-dichloropyrimidine~5~carbonyl chloride (500 mg, 2.38 mmol) in dichloromethane (30 mL) was added methanol (87.6 mg, 2.73 mmol) and diisopropy!eihylamine (369 mg, 2,86 mmol) at 0 °C. The resulting mixture was stirred for 1 h at 0 °C. Then the solvent was removed. The residue (461rng, 94%) was dissolved in IPA (20 ml,) and followed by the addition of fr ¾y-4-ammocyclohexanol (301.6 mg, 2.62 mmol) then DIEA (461.4 mg, 3.57 mmol) dropwiseiy. The resulting mixture was stirred at 0 °C for 90 min. After which buiyiamine (208,8 mg, 2.86 mmol) was added, followed by DIEA (461.4 mg., 3.57 mmol). The resulting mixture was stirred at room temperature for 3 h. Water was then added. The resulting mixture was extracted with EtOAc (3X). The combined organic layers were dried (NaaSQTj, filtered and concentrated. The residue was purified on ISCO to give methyl 2-(butyiamino)-4-(((?ra»i^^

(682.6 mg, 89% over 3 steps). Ή NMR (400 MHz, CDC1₃) δ 9.21 (s, 1H), S.77 (s, 1H), 6.29 (s, 1H), 4.81 - 4.64 (m, 1H), 4.51 (s, 3H), 4.46-4.38 (m, 1H), 4.13-4.1 ί (m, 2H), 2.89-2.81 (m, 2H), 2.74 (d, J - 9.7 Hz, 2H), 2.35 - 2.25 (m, 2H), 2.23 - 2.00 (m, 6H), 1 ,67 (t, J- 7.2 Hz, 3H); ³³C NMR (101 MHz, CDC1₃) δ 167.9, 162,5, 161.3, 160.3, 95.5, 69.7, 51.2, 48.3, 41. L 33.8, 31 ,7, 30.3, 20.1, 13,8; MS m/z 323.20 [M+Hf .

2-(Butylamino)-N-f4-fluoro^

A mixture of methyl 2-(butylamino)-4-((( r ra-4-hydiOxycyclohexyl)amino) pyriraidine-5-carboxylate (682.6 mg, 2.12 mmol) and lithium hydroxide monohydrate (888.4 mg, 21.2 mmol) in a mixture of methanol and water (25 mL, 3:2, v/v) was heated at reflux for 2h. Then the reaction mixture was coo!ed to room temperature and acidified by a 4. ON solution of EC) (4N) to PH 3. The resulting mixture was extracted with EtOAc (4x). The combined organic layers were dried (NajSC ) and concentrated to provide 2~(butylaraino)-4- (((lr,4r)~4-hydroxycyeIohexyl)amino)pyrimidine-5-carboxylic acid(647, 1 mg, 99%), which was used in the next step without further purifications. MS m/z 309.30 [M H]⁺.

A solution of the acid (61 mg, 0.20 mmol), 0-(benzotriazol- 1 -yl)-N,N,N' iV- tetramethyluroniurn tetrafluoroborate (TBTU, 81.4 mg. 0.25 mmol, 1.3 eq) and Ν,Ν· diisopropylethylarmne (DIEA, 77.5 mg, 0.60 mmol, 3,0 eq) in anhydrous DMF (3.0 mL) and was added 4-il orobenzylamine (37.5 mg, 0.30 mmol, l .Seq) in DMF (1.0 mL) dropwisely at room temperature. The resulting mixture was stirred for overnight, then diluted with EtOAc (15 mL) and washed with water (3x). The organic layer was dried (NaiSCi) and concentrated. The residue was purified on HPLC to give the title compound (61.5 mg, 74%) as a yellow solid. 1H NMR (400 MHz, CDCi₃) δ 9.57 (d, J = 7.4 Hz, 1H), 8.77 (s, 1H), 8.1 (s, 1H), 7.40 - 7.31 (m, 1H), 7.29 - 7.22 (m, 3H), 7.00 (t, J ^« 8.6 Hz, 2¾ 4.44 (d, J = 5.2 Hz, 2H), 4.00 (s, IK), 3.77 - 3.62 (m, 1H), 3.40 (dd, J - 13.0, 6.9 Hz, 2B), 2.15 - 2.09 (m, 2H), 2,04 (d, J= 7.6 Hz, 2H), 1.66 - 1.54 (m, 2H), 1.49 - 1.33 (m, 6H), 0.94 (t, J - 7.3 Hz, 3I-I); MS m/z 416.30 [ΜϊΉ]⁺.

Example 3

( l r,4r)-4-((2-{ButylaiTiiBO)-5-(5-(morphoUnosui.fo

yl)aB ino)cyclohexanol

General Procedure C;

4-((6-ChloropYridln-3-yl)sulibn l)mo^hoiine

A solution of 2-chloropyridine-S-suifonyl chloride (212 mg₅ 1 .0 mmol) in CH2C12 (10 mL) was added morpholine (87.1 mg, 1.0 mmol) at 0 °C. The resulting mixture was stirred at 0 °C for 10 min and then DIEA (194 mg, 1.5 mmol) was added dropwisely. The mixture was stirred at 0 °C for 2h. Then the mixture was diluted with EtOAc (15 mL) and washed with water (2x). The organic layer was dried (NaaSO^, filtered and concentrated. The residue was purified on ISCO to give the title compound as a white solid (246.1 mg, 94%). ^!H NMR (400 MHz, CDC1₃) δ 8.73 - 8.65 (m, 1H), 7.94 (dd, J^~ 8.3, 2.5 Hz, IH), 7.49 (dd, J - 8.3, 0.6 Hz, 1H), 3.74 - 3.63 (m, 4H), 2.99 (dd, J = 5.6, 3.9 Hz, 4H); ^!3C NMR (101 MHz, cdcB) δ 155.9, 148.7, 137.9, 131.1 , 124.9, 65.9, 45.8; MS w/z 263.30 [M+H .

A 10 mL microwave tube was charged with 2,4-dichIoropyrimidine-5-boronic acid pinacol ester (55 mg, 0.20 mmol), K₂C0₃ (41.5 mg, 0.30 mmol) and THF (2.0 mL). The resulting mixture was then heated to 80 °C for 15 min under Microwave irradiation. Then 4- i(6-chloropyridin-3~yl)sui.fonyl)moipholine (52.5 mg, 0.20 mmol), Pd(PPi¾)₄ (23.1. mg, 0.02 mmol), K2CO3 (41 .5 mg, 0.30 mmol), butylamine (1 16.8 mg, 1.60 mmol) and water (0.5 mL) were added sequentially. The resulting mixture was heated to !50 °C for 30 min under Microwave irradiation. The mixture was diluted with EtOAc (15 mL) and washed with water (2x), The organic layer was dried (NaaSOd), filtered and concentraied. The residue was purified on ISCO and HPLC to give the title compound as a white solid {27.4 mg, 28%) and (lr_}4r)-4-((2-(butylamino)pyrimidin-4-yl)amino)cyclohexanol (25.7 mg, 49%). Ή NMR (400 MHz, CDCla) δ 10.65 (d, J = 7.1 Hz, IH), 9,46 (t, J = 5,4 Hz, 1H), 8,87 (d, J - 2.2 Hz, 1H), 8.31 (s, III), 8.10 (dd, J = 8.6, 2.3 Hz, 1H), 7.77 (d, J - 8.7 Hz, 1 H), 4, 19 - 4.09 (m, 1H), 3.84 -- 3.68 (m₅ 5H), 3.51 - 3,44 (m, 2H), 3, 15 - 3,06 (m, 4H), 2.86 - 2.66 (m, 3H), 2.28 - 2.15 (m, 2H), 2,13 - 2,01 (m, 2H), 1.72 - 1 ,61 (m, 2H), 1.56 - 1.36 (m, 6H), 0.96 (t, J = 7.4 Hz, 3H); "C NMR (101 MHz, CDC¾) δ 159.4, 156.9, 153.1, 146.6, 142,8, 136.8, 130.2, 1 18,9, 103.4, 69.2, 66.0, 49.7, 45.8, 41.3, 33.3, 31.0, 29.5, 20.1, 13.7; MS m/z 491.30 [M+Hf,

Example 4

UNC2427A

General Procedure D:

2,,4-pichloro-,N-l4-fl

4-Fluorobenzy!amine (1.78g, 14.2 mmol) in dicMoromeihane (5.0 mL) was added into a solution of 2,4-dich1oropyrimidine-5-carbonyl chloride (3.0 g, 14.2 mmol) in dicMoromeihane (30 mL) at 0 °C. Then N,N-diisopropylethylamine (2.75g, 21.3 mmol) and 4-(dime yiamino)pyridme (17.1 mg, 0.14 mmol) were added into the mixture. The resulting mixture was allowed to warm to room temperature arid stirred for 20 min. The solvent was removed and the residue was dissolved in dichloromethane and washed with water (2x). Solvent was removed and the residue was purified on ISCO to provide the title compound (3.96g, 93%). ^!H NMR (400 MHz, CD₃OD) δ 8.73 (s, 1H), 7.42-7.35 (in, 2H)_S 7.12-7.02 (m, 2H), 4.53 (s, 2H); MS m/z 301 ,30 [M+Hf. y)-5-f(2-((3-Arn.!nopropyi)amino)-5-((4-fluorobenzyl)

((te rz-butoxvcarbon vl).amino)pentanoi c acid

i-Qrniihine (232 mg, 1 ,0 mmol), N.N-diisopropyleihylarnine (194 nig, 1.5 mmol.) were added into a solution of 2,4-dichloro-N-(4-fluorobenzyl)pyrimidine-5-carboxamide (300 mg, 1.0 mmol) i a mixture of isopropyl alcohol and DMF (10 mL, 3:2, v/v) at room temperature. The resulting mixture was stirred for overnight. Then 1/3 of the reaction mixture was added to a solution of 1,3-diaminopropane (304 mg, 4.0 mmol) in DMF (1.0 mL) at room temperature. The reaction mixture was heated at 45 °C for 2h, The solvent was removed and the residue was purified on HPLC to give the title compound as TFA salt (92 nig, 34%). ^}H NMR (400 MHz, CD₃OD) δ 8.22 (s, IH), 7.38-7.28 (m, 2H), 7.06-6.95 (m, 2H), 4.45 (s, 2H), 4.18-4.09 (m, I H), 3.69-3.53 (m, 4H), 3.08-2.99 (m, 2H), 2.05-1.97 (m, 2H), 1.91 - 1.83 (m, IH), 1.80-1.66 (m, 3H), 1.41 (s, 9H); MS m/z 534.30 [ M H i] ' .

UNC2427A

-(benzofriazoH -yl^N.iYJV'.iV-ietramethyluronium tetrafluoroborate (TBTU, 68.3 •rag, 0.2! rnmol) and irielhylamine (43.5 rag, 0.43 mmoi) were added to the solution of (S)-5~ ((2-{(3-aminoprGpyI)amino}~5~(^

butoxycarbonyl)amino)peniaiioic acid (70 mg, 0.085 rnmol) in DMF (50 mL). The resulting mixture was diluted with dichloromethane (60 mL) and stirred a room temperature for overnight. Then the solvent was removed, the residue was dissolved in dichloromethane (5.0 mL) followed by the addition of TFA (1.0 mL). The resulting mixture was stirred at room temperature for 2.0 h. Then the solvent was removed and the residue was purified on HPLC to provide the title compound (UNC2427A) as TFA salt (27.4 mg, 46%); ^lH NMR. (400 MHz, CD3OD) δ 8.19 (s, I H), 7.37-7.26 (m, 2H), 7,06-6.97 (m, 2H), 4,44 (s, 2H), 4,02-3.97 (m, IH), 3.97-3.89 (m, I H), 3.81-3,71 (m, !H), 3.68-3.60 (m, I H), 3.28-3.12 (m, 2H), 2.87- 2.80 (m, 1 H), 2.01-1.92 (m, 2H), 1 ,91-1.82 (m, i H). 1.80-1.64 (m, 3B). MS m z 416.25 [M+Hf,

Table 1 describes compounds prepared following procedures described in Example 4 (General Procedure D), using appropriate reagents. (Note: Mer 1C50: ++++· means < 10 nM; ■ - means between 10-lOOnM, ++ means between 100 tiM-i uM; + means between 1-30 μ,Μ; - means inactive.)

(m, 3H), 1.73- 1.52 (rn, 5H), 1 .48-1.34 (m, 3H); MS m/z 444.30 f +Hf.

Ή NMR (400 MHz, CD₃O.D) δ 8.20 (d, J - 0.9 Hz, IH), 7.38-7.29 (ra, 2H), 7.07-6.99 1 (m, 2H), 4.44 (s, 2H), 3.88- 3.66 (m, 4H), 3.51-3.32 (m, 2H), 3.21-3.1 1 (ra, I H), 2.98- 2.93 (m, 4H), 2,89-2.77 (m, I H), 1 ,98" Ϊ .85 (ra, 2H)_: 1.84- 5.58 (m, 5H), 1.56--1 .48 (m, HI), 1.46- 1.29 (m, 5H); MS m/z 458.30 [ +H] , UNC2479A ¾ NMR (400 MHz, CDjOD) o 8.2] (s, IH}, 7.36-7.30 (m, 2H), 7.07-6.99 (m, 2H), 4.45 (s, 2H), 3.94-3,85 (m, IH), 3.80-3,74 (m, IH), 3.74-3.65 (m, ΪΗ), 3.55-3.45 (m, 2H),

3.38 -3.30 (ra, IH), 3.23-3.11

(m, IH), 2.96 (s, H), 2.89- 2.80 (m, IH), 1.97- 1,81 (m, 2H), .77-1.55 (m, 5H), 1.54-

1.43 (m. 2H), 1.43-1.21 (m,

7H); MS w¾ 472,30 [M-HKf.

UNC2431A Ή NMR (400 MHz. CD₃OD)

<58.22 (s, IH), 7.37-7.28 (m, 2H), 7.07-6.97 (m, 2H), 4.45 (s, 2H), 3.89-3.79 (m, 2H),

3.71-3.58 (m, 2H), 3.58-3.49 (m, IH), 3.44-3.34 (m, IH),

2.95 (s, IH), 2.90-2.80 (m,

IH), 1.98-1.84 (m, 2H), 1.74- 1.66 (rn, 2H), 1,65-1.57 (m, 2H), 1.56-1.51 (m, IH), 1.50- 1.42 (m, IH), 1.39-1.25 (m, 8H); MS m/z 486.30 [M+Hf.

UNC2342A ¾ NMR (400 MHz, CD₃OD)

<5 8.44 (d, J - 2.5 Hz, IH), 7.81-7.73 (in, 2H), 7.53-7.46 (ni 2H), 4.33 (s, 2H), 4.07- 3,93 (m, 4H)_; 3,82-3.64 (m, 4H), 3,41-3.34 (m, 2H), 3.28-

3,07 (m, 4H), 2.90-2.82 (m,

IH), 2,04-1.95 (ra, 2H), 1,94-

(m,

(ddd, (ai, 4.45 (ta, 4.46

Example S

UNC2324A

General Procedure E:

UNC2343A

LiOH

THF,'H₂0*^"

UNC2340A UNC2324A

UNC2343A

To a solution of 2₅4-dich-k>ropyriB idine--5-carbonyI chloride (500 rag, 2.38 mmol) in dichloromethane (30 mL) was added methanol (87.6 mg, 2.73 mmol) and dnsopropylethylamme (369 mg, 2.86 mmol) at 0 °C. The resulting mixture was stirred for at 0 °C 1 h. Then the solvent was removed. The residue (412mg, 2.0 mmol) was dissolved in 1ΡΛ (20 mL) followed by the addition of Z -Ornithine (465 nig, 2,0 mmol) and N,N- diisopropylethylaraine (388 mg, 3,0 mmol). The resulting mixture was stirred at 0 °C for 90 min, then dichloromethane (5.0 mL) was added. The resulting mixture was stirred at 0 °C for 1.0 h and at room temperature overnight. Solvent was removed and the residue (MS m/z 403,30 [M+H]*) was dissolved in DMF (5.0 mL) and was added dropwise into a solution of 1 ,4-diaminobutane (1.68g, 19.1 mmol) in DMF (1.0 mL) at room temperature. The resulting mixture was heated to 45 °C for Ih, The solvent was removed and the residue was dissolved in ethyl acetate (35 mL) and washed with water (3x). The organic layer was dried (Na₂S0₄), filtered and concentrated. The residue was purified on HPLC to provide (5)-5-((2-((4- aminobuty3)amino)-5-(methoxycarb^

amino)pentanoic acid as a semisolid (MS m/z 455.30 [M+H ⁺). The semisolid (595 mg, 1.31 mmol) was dissolved in DMF (150 mL), then TBTU (546.4 mg, 1.70 mmol) and DIEA (508 mg, 3.93 mmol) were added sequentially. The resulting mixture was stirred at room temperature overnight. The solvent was removed. The residue was dissolved in ethyl acetate and washed with water (3x). The organic layer was dried

filtered and concentrated. The residue was purified on HPLC to provide the totle compound (UNC2343A). ^l MR (400 MHz, CD₃OP) 3 8.42 (s, 1H), 4.08-3.99 (m, IH), 3.90-3,84 (m, 3H), 3.59-3.47 (m, 2H), 3.46-3.31 (m, 2H), 3.28-3.21 (m, IK), 3.09-2.95 (m, 1H), 1.90-1.52 (m, 8H), 1.51- 1.32 (ra, 9H); MS m/z 437.30 [M+H1⁺.

UNC2340A

Lithium hydroxide (200 mg, 8.3 mmol) was added to a solution of U C2343A (724 mg, 1 ,66 mmol) in- a mixture of THF and ¾0 (20 mL, 3:2, v/v). The resulting mixture was heated at 75 °C overnight. Then the reaction mixture was acidified to pH 4, then extracted with amixiure of CH₂CI₂ and IP A (3:1, v/v) to give the title compound (U C2340A) (406 mg, 58%). Hi NMR (400 MHz, CD₃OD) δ 8.36 (s, IH), 8.11 (s, IH), 4 J 2-4.02 (m, IH), 3.61 -3.47 (m, 2H), 3,34 (s, IH), 3.28-3.17 (ra, IH), 3.06-2.93 (m, IH), 2.90-2.84 (m, I H), 1.89-1.52 (m, 7H), 1.42 (s, 9H); MS m/z 423.25 [M+E†.

U C2324A

4-Fluorobenz lamine (65.1 mg, 0.5 mmol), TBTU (128.2 mg, 0.4 mmol) and triethylaniine (68 mg, 0.67 mmol) were added to a solution of U C2340A (40 mg, 0,095 mmol) in anhydrous DMF (20 mL) at room temperature. The resulting mixture was stirred for 2h, then solvent was removed, the residue was dissolved in CFi₂(¾ (30 mL) and washed with water (2x). TFA (1.0 mL) was then added and stirred at room temperature for 2,0 h, condensed and purified on HPLC to provide the title compound (UNC2324A) (26 mg, 52%). Hi NMR (400 MHz, CD.,OD) S 8.19 (s, IH), 7.37-7.26 (m_s 2H), 7.07-6.96 (m, 2H)₅ 4.44 (s, 2H)_S 3.88-3.82 (m, IH), 3.77-3.68 (m, IH), 3.58-3.47 (m, 2H), 3.43 -3.35 (m, I H), 3.26-3.13 (m, 2H), 2.98-2.93 (m, 2H), 2.92-2.84 (m, I H), 1.92-1.81 (m, 3H), 1.81 -1.53 (m, 5H), 1.44- ί .29 (m, IH); MS m/z 430.20 [M+H]⁺.

Table § describes compounds prepared following procedures described in Example 5 (General Procedure E), using appropriate reagents.

Structure Compound_ID Mer Physical Data

IC₅₀ MS m z (M+l) or/and Ή

NMR

^'UNC2589A ++ ^lH NMR (400 MHz, CD₃OD)

δ 8.21 (s, IH), 7.39-7.35 (m,

HN 4H), 4,50-4.47 (m, 2H), 3.97- 3.9 ! (m, 3H), 3.87-3.83 (m, ! H), 3.40-3.33 (ra, 5H), 3,09- 3.01 (m, 4H), 2.87 (s, 4H), 1. 3-1.82 (m, 4H)₅ 1.79-1.70 {ra, 2H), 1 .69-1.57 (m, 3H), 1.44-1.30 (in, 2H); MS m/z

δ

Hz, H), (dd, J On,

(s, H), 13.3 6H),

(m,

Example 6

UNC3263A

General Procedure F:

UNC3263A

2,4-Dich ro-A^r- (4-fluoroph

A solution of 2_}4-dichloropyrimidine-5-carbonyl chloride (3.35 g, 15.8 mrno!) in dichioromethane (53 mL) was added (4-iIuorophenyl)methanaxnine (1.32 g, 10.56 mmol) and DiEA (3.7 mL, 21 mmoi) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, the solvent was removed, and the residue was purified by ISCO silica gel column, to provide the title compound (1.97 g, 62%) as a yellow solid.

A solution of 2,4-dichIoro-N-[(4-fI«orophenyl)methyl]pyrimidme-5-carboxaraide (97 mg, 0.325 mmol) in -PrOH (5 mL) was added 7-aminohept-l-en-4-ol (42 mg, 0.325 mmoi) and DIEA (85 _,uL, 0.488 mmoi) at 0 °C. The mixture was allowed to warm to room temperature and stirred overnight. To the reaction was added oct-7-en-l -amine (207 mg, 0.975 mmol) and DIEA (85 LIL, 0.488 mmol). The reaction was heated at 70 °C for 6 h and the volatiles were removed under a reduced pressure. The residue was dissolved in CH2CI2 (4.0 mL) and washed with ¾0 (2.0 mL). The ¾0 layer was extracted with CH₂C1₂ (2 ^χ 20 mL); the organic layers were combined, dried (NaiSO^), and the solvent was removed under a reduced pressure. The residue was purified by ISCO silica gel column to provid the title compound (39 mg, 25%) as a white solid. Ή N.MR. (400 MHz, CDCI.3) δ 8.70 (s_s 1H), 8.09 (s_s 1H), 7.29 (dd, J = 8.7, 5.3 Hz, 2H), 7.07-6.98 (m, 2H), 6.08 (s, 1H), 5.90-5.71 (m, 2H), 5.18-5.04 (m, 1H), 5.03-4.89 (m, 2H), 4.51 (d, J ~ 5.7 Hz, 2H), 3.70 (s, 1 H), 349 (s, 2H), 3.38 (dt, J = 9.7, 4.8 Hz, 211), 2.35-2.12 (m, 2I¾ 1.80 .1.68 (m, 2H), 1 ,59 (s, 9H), 1.44-1.31 (m, 5H).

A^r"[(4-Fluorophenyl)methyij-6-h ydroxy-2, 16, ί 8,21 -t traazabicyclof 15.3.1 Ihenieosa- 1(20), 17 3263A)

A solution of N-[(4-iluorophenyl)methyl]-4-[(4-hydroxyhept-6~en-l-y!)amino]-2- [(oet-7-en-l-yl)amino]pyrimidine-5-carboxamide (34 mg. 0.07 mmol) in toluene (35 mL) was added benzoquinone (1.5 mg, 0.014 mmoi) and Grubb's 2^nd generation catalyst (6.0 mg, 0.007 mraol), The mixture was refluxed under Ar ovemight. After which more catalyst was added (6.0 mg), and heated at reflux for 8 h. Tlie voiatiles were removed and the residue was purified by IS CO silica gel column to provide the RCM product as a crude brown solid. The residue was dissolved in MeOH (1.0 mL) and Pd/C (10 mg) was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 24 h. The mixture was filtered through C elite and washed with MeOH then purified by HPLC to afford the title compound as a white solid (5.3 mg, 16%). ^lH NMR (400 MHz, CD₃OD) δ 8.21 (s, IH), 7.37 (dd, J = 8.8, 5,4 Hz, 211), 7.05 (t, J - 8.8 Hz, 2H), 4.47 (s, 2H), 3.73-3.60 (m, 2H), 3.58-3.41 (ra, 3H), 1 ,84-1.72 (m, 2H), 1.72-4.62 (m, 2H), 1.61-1.45 (m, 5H), 1.43-1.26 (ra, 11H). MS m/z 458.3 [M+Hf .

Table | describes compounds prepared following procedures described in Example 6

Table § describes compounds can be prepared following procedures described in Example 6 (General Procedure F), using appropriate reagents.

Structure Compound ID Mer Physical Data

ICso_ -MS /z (M-i-1) or/and ¾

Example 7

UNC3017A, U C3018A & U C3019A

General Procedure G:

UNC301 A

UNC30f9A

A solution of (S -6ramino-2-((i«rf-b toxycarbonyl)ainmo)hexanoic acid (0.042 g, 0,10 nmiol) in DMSO was added hexane~l ,6~diamme (0.046 g. 0,40 mmol). The resulting mixture: was heated at 100 °C for 2 h. After coo!ed to room temperature, the solvent was removed under reduced pressure. The resulting residue was purified by reverse phase ISCO column to provide title compound (0.041 g, 79%). ^lH NMR (400 MHz, C δ 7,91 (s, 1H), 4.13-4.02 (111, I H), 3.57 (t, J- 12, 2H), 3.51-3.38 (bs, 2H), 2.94 (t, J- 12, 2H), 1.92- 1.80 (m, IH), 1.75-1.62 (m, 7H), 1.57-1.36 (m, 15H); MS m/s 517.3 [M+Hf.

A sol ution of {S)-6-((2-((6-aminohexyl)amino)-5-bromopyrimidin-4-yI)amino)-2-((tert- butoxycarbonyl)amino)hexanoic acid (2.1 1 g, 4.08 mmol) arid DiEA (1 .78 mL, 10.19 mmol) in 20 mL DMF and a solution of HATU (2,01. g, 5.28 mmol) in 20 mL DMF were added to 200 mL of DMF in 16 h. After addition, the resulting mixture was stirred for I h. The solvent was removed under reduced pressure. The residue was purified by ISCO silica gel column to provide the desired bromide (0,87 g, 43%) containmated with small amount of impurities. MS m/z 499.3 [M+Hf .

A solution of the bromide (0.66 g, ί .32 mmol) in DMF (6.6 mL) was added PdCl₂(dpp ^'CH₂Cl₂ (0.1 1 g, 0.13 mmol), CuBr (0.036 g, 0.26 mmol), ₂C0₃ (0.56 g, 9.96 mmol), (5~( 1 ,3-dioxolan-2-yl)pyridin-2-yl)boronic acid lithium hydroxide (0.86 g, 9.96 mmol) and ¾0 (1 ,7 mL) at. room temperature. The resulting mixture was heated at 120 °C for 30 min under. After cooled to room temperature, the mixture was filtered over Ceiite. The solvents were removed under reduced pressure. The crude residue was purified by ISCO silica gel column to provide the desired acetal (0.76 g, 63%) containraated with small amount of impurities. MS m/z 570,4 [M HT .

A solution of the the acetai (0.47 g, 0.83 mmol) in acetone (10 mL) was added p~TsOH^'¾0 (0.24 g, 1.25 mrnol) and H₂0 (2.0 mL). After stirring at room temperature for 16 h, the reaction mixture was quenched with a sat, aq solution of ΝαΗ€0₃ and extracted with EtOAc (3X). The combined organic layers were dried (NajSO ) and concentrated. The resulting residue was purified by ISCQ silica gel column to provide the desried aldehyde (0.42 g, 96%) contaminated with small amount of impurities. MS m/z 526.4 [M+H]⁺.

A solution of the aldehyde (0.53 g, 0.1 mmol) in CH2CI2 (2.0 mL) was added morpholfne (0.013 mL, 0.15 mmol) and acetic acid (0.04 mL). The resulting solution was stirred at. room temperature for 2 h, then NaB(OAc)jH (0.043 g, 0, 15 mmol) was added. After stirred at room temperature for 16 h, the reaction was quenched with a sat. aq. solution of NaHCOs and extracted with EtOAc (3X), The combined organic layers were dried (Na₂S0 ) and concentrated. The residue was dissolved in a mixture of CH2CI2 (2.0 mL) and TFA (1.0 mL). After stirred at loom temperature for 2.0 h. the reaction was concentrated and the residue was purified by prep-HPLC to provide the desired product UNC3017A (0.046 g,

93%). 1H NMR (400 MHz, CD₃OD) δ 8.88 (s, 1H), 8.41 (s, 1 H), 8.22 (d, J - 8,4 Hz, ΪΗ), 8.01 (d, J = 8.4 Hz, 1H), 4.52 (s, 2H), 4.06 (d, J = 10.7 Hz, 2H), 3.96 3.79 (m, 4H), 3.77- 3.67 (m, I H). 3.57 (td, J= 12.2, 5.2 Hz, 2H), 3.45 (d, J = 12.4 Hz, 2H), 3.39-3.23 (m, 3H)₃ 3.02-2.93 (m, 1H), 1.96 (dd, J = 10.2, 4.6 Hz, 2H), 1.86-1.51 (m, 7H), 1.42 (d, J = 4.7 Hz, 5H); MS m/z 497.4 [M+Hj\

A solution of the above aldehyde (0.53 g_> 0.1 mmol) in CH2CI2 (2.0 mL) was added N-methylpiperazine (0.017 rnL, 0.15 mmol) and acetic acid (0.04 mL). The resulting solution was stirred at room temperature for 2 h, then NaB{OAc>3H (0,043 g, 0.15 mmoi) was added. After stirred at room temperature for 16 h, the reaction was quenched with, a sat. aq. solution of NaHC(¾ and extracted with EtOAc (3X). The combined organic layers were dried (NaiSO/j and concentrated. The residue was dissolved in a mixture of CH2CI2 (2.0 mL) and TFA (1,0 mL). After stirred at loom temperature for 2.0 h. the reaction was concentrated and the residue was purified by prep-HPLC to give the desired product U €3018A(0.Q49 g, 98%). ^!H NMR (400 MHz, CD3OD) δ 8.91 (d, J - 1.7 Hz, IH), 8.40 (s, 1H), 8.27 (dd, J - 8.5, 2,0 Hz, Hi), 8.01 (d, J - 8.5 Hz, I H), 4.61 (s, 2H), 3.91 (t, J = 5.4 Hz, I H), 3.88-3.61 (m, 10H), 3.61-3.51 (m, 2H), 3.39-3.34 (m, IB), 3.02 (s, 3H), 3.00-2.92 (m, IH), 2.03-1.89 (m, 2H), 1.87-1.50 (m, 7H), 1.48-1.35 (in, 5H); MS m/z 510,4 M+H .

A mixture of aldehyde (0.053 g, 0.1 mmol) in 10 mL /BuOH was added NaCiOi (0,034 g, 80%, 0.3 mmol), Na¾P0₄ (0.041 g, 0.3 mmol), 2-Me~2-Butene (0, 1 1 mL, 1 mmol) and 2 mL H₂O. After stirring 16 h at room temperature, the reaction was quenched with sat. aq. Na₂S₂0₃, acidified with diluted aq, HCl to pH 4 and extracted with EtOAc (3X). The combined organic layers were dried (Na₂S0₄) and concentrated, The residue was dissolved in 3 ml, DMF. To this solution was added HATU (0.042 g, 0.11 mraol), followed by Λ\Ι~ dimethylpiperidin-4-amine (0,014 g, 0.1 1 mmol). After stirring for 16 at room temperature, the reaction mixture was condensed under vacuum and purified by Prep-HPLC, The Boc protected intermediate was dissolved in 2 mL C¾C1₂ and 1 n L TFA and stirred for 2 h. After evaporating the solvents, the residue was purified by Prep-HPLC to provide the desired product U C3019A (0.026 g, 47%). Ή NMR (400 MHz, CD3OD) δ 8.70 (s, 1H), 8.41 (s, 1 H), 8.02-7.93 (m, 2H), 3.92-3.50 (m, 8H), 3.39-3.33 (m, 1H), 3.23 (bs, i l l), 3.10-2.75 (m, 8H)₅ 2.24 (dd, J - 24.3, 1 1 .4 Hz, 2H), 2.15-2.02 (m, 2H), 2.02-1.88 (m, 2H), 1.87-1.48 (m, 8H), 1.45-1.37 (m, 4H); MS m/z 552,4 [M+H ,

Example 8

UNC3588A

General Procedure H

5-Bromo-A¾.-.(but-3-en-.l-y.l)-iV¾-.(5-((te

2.4-diamine

A solution of 5-bromo-2,4-dichloropyri.midine (0.29 g. 1 .28 mmol) in isopropaaol (3.0 mL) was added 5-((ier butyidimethylsilyl)oxy)dec-9-en-l-amine (0,38 g, 1.34 mmol) and DIEA (0.27 mL, 1.54 mmol) at 0 °C. The reaction solution was stirred at room temperature for 3 l . The solvent was removed under a reduced pressure to provide a yellow residue, which was dissolved in DMSO (5.0 mL), B ut-3 -en- 1 -amine (0.47 mL, 5.12 mmol) was added. The resulting mixture was heated at 1 10 °C for 16 h, then diluted with Et₂0 and quenched with brine. The aqueous layer was extracted with Et₂0 (3X). The combined organic layers were dried (Na₂S0₄) and concentrated. The residue was purified by ISCO silica gel column to provide desired product (0.58 g, 89%). 1H MR (400 MHz, CDCi₃) δ 7.85 (s, 1 H), 5.9.1-5.72 (m, 2H)_} 5.18-4.91 (m, 5H), 4,85 (t, J= 4.9 Hz, 1H), 3.65 (p, J= 5.4 Hz, 1H), 3.47-3.37 (m, 4H), 2.34 (qt, J = 6.8, 1.3 Hz, 2H), 2.03 (q, J - 6,5 Hz, 2H), 1.64-1.53 (m, 2H), 1.51-1.33 (m, 8H), 0.88 (s, 9H), 0.04 (s, 3H), 0.03 (s, 3H); MS m/z 51 1.3 [M+H]⁺.

A solution of

ert-butyldimethy!siiyl)oxy)dec-9- en-l-yl)pyrimidine-2,4-diamine (0.26 g, 0.50 mmol) and benzoquinone (0.009 g, 0.08 mmol) in toluene (20 ml,) was added Greta's catalyst (0.027 g, 0.04 mmol) in toluene (5.0 mL) over 1. h at 110 ^l'C. The resulting dark brown solution was heated at 1 10 °C for another hour. After cooled to 60 °C, 2-mercaptonicotinic acid (0.39 g, 2.5 mmol) was added and stirred at 60 °C for 2 h. After cooled to room temperature, the reaction mixture was filtered over Ceiite and washed with CH2CI2, The filtrate was concentrated and the residue was purified by ISCO silica gel column to provide the macrocyclic intermediate as a mixture of E and Z olefin isomers (0.19 g, 80%). MS m/z 483.3 [M+Hf .

A schlenk flask containing LiCi (0.028 g, 0.66 mmol) and stir bar was flame dried. After cooled to room temperature, CuCl (0.054 g, 0,55 mmol) and Pd(PPl¾)4 (0. 13 g, 0.01 1 mmol) was added. The reaction mixture was vacuumed and refilled with argon (4X). The intermediate from previous step (0.054 g, 0.11 mmol) in DMSO (4,0 mL), and Bi¾SnPy (0,049 g, 0,13 mmol) were added under argon. The resulting reaction mixture was freeze- thawed under argon (4X). The mixture was heated at 60 °C for 2 d, then diluted with EiGAc. quenched with brine and a saturated aq, solution of NaHCOj. The organic layer was washed wit a sat. aq solution o£ NaHC(¾ (3X). The combined aqueous layers were extracted with EtOAc (3X). The combined organic layers were dried (NaiSC^) and concentrated. The residue was purified by ISCO silica gel column to provide Stille coupling products (0.040 g, 75%). MS m/z 482.4 [M+H ,

A solution of the Stille coupling product (0.040 g. 0.083 mmoi) in MeOH (5.0 mL) was added a cone. HC1 solution (0.50 .mL). The resulting mixture was stirred for I h and concentrated under reduced pressure. After zoetrope with MeOH (3X), the residue was dissolved in MeOH (5.0 mL) and AcOH (0.50 mL) and was added Pd/C (0.009 g, 1.0 wt%). The reaction mixture was stirred at room temperature under hydrogen for 1 d, then filtered over Celite and washed with MeOH. The filtrate was concentrated and the residue was purified by reverse-phase HPLC to provide the desired product UNC3588A (0.025 g, 82% over 2 steps). ^lH NMR (400 MHz, CD₃OD) δ 8.62 (ddd_s J - 5.0, 1.6, 0.9 Hz, 1H), 8.28 (s, 1 H), 7.96-7.82 (m, 2H), 7.39 (ddd, J - 7.3, 5.0, 1.1 Hz, 1H), 3.91-3.79 (m, IE), 3.71-3.53 (m, 3H), 3.49-3.38 (m_s 1H), 1.92-1.78 (m, 1H), 1.76-1.65 (m, 3H), 1.62-1.34 (m, 14H). MS m/z 370.3 M+H]⁺.

Example

UNC32 5A

General Procedure I:

UNC329SA A solution of the bromide intermediate (0.17 g, 0.34 mmol) in DMF (2,0 mL) was added Pd(dppf)Cl₂-CH₂Cl2 (0,028 g, 0.034 mmol), CuBr (0.098 g, 0,68 mmol), K₂C0₃ (0, 14 g, 1 ,02 mmol), (5-(l₅3~dioxoian-2-yl)pyridin-2-yl)boiOnic acid lithium hydroxide (0.22 g, 1.02 mmol) and water (0,50 mL). The resulting mixture was heated at 120 °C for 30 min open to air. The mixture was filtered over Celite at room temperature. The solvents were removed under a reduced pressure and the residue was purified by ISCO silica gel column to provide the desired coupling product (0.053 g, 28%) contaminated with small amount impurities; MS m/z [M+Hf.

A solution of the coupling product (0.053 g, 0.10 mmol) in acetone (10 mL) was added >~TsOH,¾0 (0.029 g, 0.15 mmol) and hhO (0,80 mL), The reaction mixture was stirred at room temperature for 16 h, then quenched with a sat, aq solution of NaHCOj and extracted with EtOAc (3X). The combined organic layers were dried (Na₂S0₄) and concentrated. The resulting residue was purified by ISCO silica gel column to provide the desired aldehyde intermediate (0.031 g, 78%) contaminated with small amount impurities; MS m/z 554.4 M+Hf .

A solution of the aldehyde (0.031 g, 0,078 mmol) in C¾C¾ (2,0 mL) was added morphoiine (0.01 mL, 0.12 mmol) and 0,08 mL acetic acid. The resulting solution was stirred at room temperature for 2 h, then NaB(OAc)₃H (0.033 g, 0.16 mmol) was added. The reaction mixture was stirred at room temperature for 16 h, quenched by a sat. aq, solution of NaHCOs and extracted with EtOAc (3X). The combined organic layers were dried (NaaSOT) and concentrated. The residue was dissolved in MeOH (5,0 mL) and was added Pd/C (0.015 g„ 5 wt% Pd C). The reaction mixture was stirred under hydrogen atmosphere at room temperature for 16 h, then .filtrated over Celite and washed with MeOH. The filtrate was concentrated and the residue was purified with reverse-phase HPLC to provide the desired product UNC3295A (0.0096 g, 26%). Ή NM (400 MHz, CD₃OD) δ 8.73 (d, J - 1 ,8 Hz, IB), 8.40 (s, 1H), 8.06 (dd, J- 8,5, 2.2 Hz. 1H), 7.96 (d J= 8.5 Hz, 1 H), 4.40 (s, 2H), 3.98- 3.80 (ra, 5H), 3.70-3.5 Ϊ (m, 3H), 3.49-3.38 (m, 1H), 3.29 (bs_> 4H), 1.90-1.79 (m, 1H), 1.77- 1.65 (m, 3H), 1.62-1.36 (m, 14H); MS m/z 469.4 [M+H]⁺. Table 6 describes compounds prepared following procedures described in Example 9 (GeneraJ Procedure I), using appropriate reagents.

Structure Compound_JD Physical Data

Example 10

UNC3096A

General Procedure J:

A solution of methyl 2_>4-dichloropyrimidine-5-carboxylate (252 mg, 1.22 mmol) in /^"- PrOH (6 mL) was added 2-(2-aminoethoxy)ethanol (122 μΐ,, 1.22 mmol) and IEA (319 pL, 1.83 mmol) at 0 °C. After 1 ,5 h the volatiies were removed imder a reduced pressure and the residue was purified by ISCO silica gel column to provide the title compound (243 mg, 72 %) as a white solid. 1H N R (400 MHz, CDC1₃) δ 8.67 (s, 1H), 3.90 (s, 3H), 3.82-3.74 (m, 4H), 3.70 (t, J - 5.2 Hz, 2H), 3.67-3.61 (m_} 2H), 2.17 (t, J - 6.3 Hz, 1H).

Methyl 2-chloro~4-(8.,8,9 ^etrame^

carboxylate

A solution of methyl 2-chloro~4- { [2-(2-h.ydroxyethoxy)ethyl]am.ino}pyrimidine-5- carboxylate (99 mg, 0.36 mmol) in DMF (720 uL) was added imidazole (49 mg, 0.72 mmol) followed by TBD SC1 (60 mg, 0.396 mmol). The reaction mixture was stirred at room temperature for 1 h, diluted with ¾G (2 raL) and extracted with C¾C (3 ^x 2 mL), The combined organic layers were washed with brine (2 x 2 mL), dried (Na₂S0 ) and concentrated. The residue was purified by ISCO silica gel column to provide the title compound (137 nig. 98 %) as a colorless oil.

Methyl 2-|^'(5-hydroxypentyl)amino]-4-(8.8.9,9-tetramethyl-4,7-dioxa- 1 -aza-8-siladecan- 1 - yi)pyrimidine-5-carboxylate

A solution of methyl 2~chloro-4-(8,8_;9_?9 etramethyl-4,7-dioxa-i-aza-8-siladecan-i-- yI)pyrimidine-5-carboxylaie (133 mg, 0.341 mmol) in z^'-PrOH (3.4 mL) was added 5- arninopentan-1-οϊ (185 μΤ, 1.7 mmol) and DIEA (89 μΤ, 0.51 1 mmol). The reaction mixture was stirred at room temperature overnight. The solvents were removed under a reduced pressure and the residue was purified by ISCO silica gel column to provide the title compound (156 nig, >99%) as a colorless oil.

A solution of methyl 2-[(5¾droxypentyl)amino j-4-(8,8,9₃9~tetramethyl-4,7-dioxa-l- a .a-8-siladecaii-l-yl)pyrimidine-5-carboxylate (150 mg, 0.328 mmol) in 0¼(¾ (3.3 mL) was added DIEA (143 μΤ, 0.82 mmol) then methane sulfonylchloride (28 μΐ, 0.361) at 0 °C. The reaction mixture was stirred for 30 mm and diluted with J¾0 (12 mL). The organic layer was washed with brine (10 mL) and dried to provide the crude mesylate that was used for the next step without further purification. The mesylate was dissolved in THF (7,3 mL) and TBAF (1M i THF, 585 L, 0.585 mmol) was added. The reaction mixture was stirred at room temperature overnight. The solvents were removed under a reduced pressure and the residue was purified by ISCO silica gel column to provide the title compound (32 mg, 34%) as a white solid. Ή NMR (400 MHz, CDC1₃) 6 8.57 (s, 1 H , 3.86-3.79 (m_s 7K), 3.79-3.73 (ra, 2H), 3.72-3.66 (m, 5H), 3,64-3.59 (m, 2H), 2.32 (dd, J- 9.3, 3.6 Hz, 1H)₅ 1 .72-1.64 (m, 2H), 1.59 (dd, J- 10.8, 5.7 Hz, 4H).

5 ,8-Dioxa-2 -14 j 6.19-tetraazabicyclo[l 3.3., 1 jnonadega-l (18), 15(19), 16-triene-l 8-carboxylic acid

A solution of methyl 5,8-dioxa-2_s 14,16,19-tetraazabicyc!o [ 13.3.1 jnonadeca- 1 (18), 15(19), 16-triene-i 8-carboxyiate (32 mg, 0,099 mmol) in MeOH (1.4 mL) was added a 4.0 M OH solution (250 μϊ,). The reaction mixture was heated at 60 °C overnight, The reaction was cooled and the MeOH was removed under a reduced pressure. The mixture was acidified with a 4.0 N HC1 solution to pH - 2. The aqueous layer was extracted with 3:1 CHaCfc/i-PrOH (3 x 5 mL). The combined organic layers were dried (Na;)S0 ) and concentrated to afford the title compound (35 mg, >99%) as a white solid. 3096 A)

A solution of 5,8-dioxa-2_s 14,16,19-tetraazabicycio[l 3.3.1 jnonadeca-l (18), 15(19),16- triene-18-carbox lic acid (30 mg, 0.099 mmol) in DMF (1.0 mL) was added [6~(lH-pyrazol- l-yl)pyridm^»3-yl]inemanamine (17 mg, 0.099 mmol) and DIEA (34 uL, 0.197 mmol) followed by HATU (41 mg, 0.108 mmol). The reaction mixture was stirred at room temperature overnight, quenched with a 1.0 M NaOH solution (2.0 mL) and extracted with CH₂CI₂ (2 x 2 mL). The combined organic layers were dried (NaiSO^) and concentrated. The residue was purified by HPLC to afford the title compound (37 mg, 67%) as a light yellow solid. ^!H NMR (400 MHz, CD₃OD) δ 8.62 (dd, J= 2.7, 0.4 Hz, 1H), 8.50 (d, J ^ 1.9 Hz, 1 H), 8.32 (s, 1H), 8.15 (dd, J™ 8.6, 2.3 Hz, 1H), 8.03 (d, J^~ 8.5 Hz, 1H), 7,85 (d, J= 1.3 Hz, 1H), 6.61 (dd, J = 2.7, 1.7 Hz, 1H), 4.59 (s, 2H), 3,85-3.63 (m, 10H), 3.63-3.55 (m, 2H), 1.81- 1.65 (m, 6H). MS m/z 467.3 [M+H .

Table j§ describes compounds prepared following procedures described in Example 10 (General Procedure .1), using appropriate reagents.

Structure Compound_iD Mer Physical Data

ICso MS m/z (M+l ) or/and ^lH

NMR

Example 11

UNC3040A

General Procedure K:

Ethyl 2.8.9.10.17.19.22-heptaazatricvcIoi 16.3.1.1 ⁷,ⁱ⁰1tficosa- 1 (21V7(23),8.18f 22), 19- entaene-2. -carboxylate

A solution of 2,4-dichloropyrimidine~5-earbonyi chloride (1.00 g, 4.76 mmol) in ethanol (6.0 mL) was added DIPEA (2.5 raL, 14,4 mmol) slowly at 0 °C under nitrogen. After 30 mm, hex-5-yn-I -amine (0.476 g, 4.91 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 3.5 h, then was added dropwise to a solution of 6-azidohexan- 1 -amine (0.801 g, 5.64 mmol) in ethanol (4.0 mL) at 50 °C After the reaction was complete (monitored by LCMS), the mixture was diluted with water (10 mL) and concentrated under a reduced pressure and filtered. The yellow solid was washed with water and dried under vacuum to be used in the next step without further purification (0.723 g, 39% over 3 steps).

A solution of the yellow solid (0.130 g, 0.336 mmol) in dry CH2CI2 (25 mL) was added TBTA (1.6 mL, 5 mg/niL in CH₂C1₂, 8.0 mg, 0.016 mmol) and Cu(MeCN)₄BF₄ (5.2 mg, 0.016 mmol). The reactio mixture was stirred under nitrogen at 45 °C for 24 h, then cooled to room temperature and concentrate. The residue was purified by silica gel column to provide the title compound (0.104 g, 80%). Ή NMR (400 MHz, CD₃OD) δ 8.34 (s, 2H), 7.58 (s, 1H), 4,36 (s, 2H). 4.22 (q, J~ 7.1 Hz, 2H), 3.34 (s, 2H), 3.19 (s, 2H), 2.82-2.66 (m, 2H), 1.84 (s, 2H), 1.67 (s, 2H), 1.62 1.44 (m, 4H), 1.40-1.02 (m, 7H).

2.8.9.10 J 7 J 9,22-Heptaazatricyclon 6.3.1.1⁷, ^l0]tricosa- 1 (2 l\7f23 .8.18(22), 19-pentaene-21 - carboxy lie acid

A solution of ethyl 2,8,9, 10, 17, 19,22-heptaazatricyclofl 6;3.1.1⁷,^l0]tricosa- l(21),7(23)_i8.18(22),19-pentaene-21-carboxylate (31 mg, 0.081 mmol) in MeOH (2,0 mL) was added an aq. OH solution (10%, 0.50 mL). The reaction was stirred at 60 °C for 12 h. Then the reaction mixture was cooled to room temperature and adjusted to pK-3 by the addition of a HCi solution. The resulting solution was extracted by a mixture of /-PrOH/ C¾C¾ (1 :3, 10 mL ^x 3). The combined organic layers were washed with water and brine and concentrated under vacuum to afford the desired product (0.029 g, quant.) as a white solid. Ή NMR (400 MHz, CD3OD) 3 8.41-8.22 (m, 1 H)_S 5.65 (s₉ 2H), 4.63-4.46 (m, 1H), 3.55-3.43 (m, 1H), 3.39-3.33 (m_s 1 H), 3.02 (t, J ^~ 6.9 Hz, 3H), 2.97-2.83 (m, I B), 2.58-2.29 (m, 3H), 2.03-1.89 (m, 1H), 1.85-1.71 (m, lH)_t 1.71-1.50 (m, 2H), 1.49-0.97 (m, 3H). jV-f l-benzylpiperidin-4-vl)-2.8,9.10.17.19,22-heptaazatrioyclof 16.3.1.1⁷, ^,Qltricosa-

1(21 ),7(23 ,8, 18(22U 9-pentaene-21 -carboxamid (UNC3040A)

A solution of 2_I8₅9,10 i7_!19_s22-HepiaazatTicy lo[16.3.1 , l⁷,^t0]tricosa^« l(21),7(23)₅8,18(22),19-pent¾ene-21 -carboxylic acid (30 mg, 0.084 .mmol) in DMF (2.0 niL) was added 1 -benzylpiperidin-4-amine (19.8 mg, 0.10 mmol) followed by HATU (38 mg, 0.10 mmol}. The reaction mixture was stirred at room temperature overnight, quenched with a 1.0 M NaOH solution (2.0 mL) and extracted with CH₂C1₂ (2 ^χ 2 ml). The combined organic layers were dried ( a₂SG₄) and concentrated. The residue was purified by HPLC to afford the title compound UNC3040A (6.0 mg, 13%) as a light yellow solid. H NMR (400 MHz, CD₃OD) 8 8.24 (s₅ 1 H), 8.08-7.93 (in, 2H), 7.64-7.46 (m, 4H), 4.54-4.46 (m, 2H), 4.33 (s, 1H), 3,59-3.40 (m, 4H), 3.22-3.05 (m, 2H), 3.02-2.93 (ra, 3H), 2.91-2.77 (m, 3H), 2.37-2.26 (m, 1H)₅ 2.25-2.13 (m, 2H), 1.98-1.86 (m, 3H), 1.79-1.70 (m, 2H), 1.66-1.50 (m, 4H), 1.30-1.10 (m, 4H); MS (ESI): 554.5 [M + Naf .

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims_., with equivalents of the claims to be included therein.

Claims

That which is claimed is:

1 , A compound of Formula Ϊ or Formula .11:

wherein:

ring A is a 5~ or 6-membered heteroaryl group, the dashed line is an optional double bond, X is N or 0. and Y is C, S or N in any location in the ring;

R^! is -R⁵R⁶ ₅ where R⁵ is a covalent bond, CI to C3 alkyi or a linker group and R^fi is eycloalkyl, heterocycloalkyl, aryl, heteroaryl, aikylcycloalkyl, aikyiheterocyc!oalkyl, alkylaryk alkyiheteroaryl or alkyi, and wherein R⁶ is optionally substituted one, two or three times with independently selected polar groups;

R² and R³ together form a linking group;

R⁴ is H, loweralkyi, halo, or loweralkoxy;

or a pharmaceutically acceptable salt thereof,

2. The compound of claim 1 , wherein R^" is a covalent bond.

3. The compound of claim I, wherein R⁵ is CI to C3 aikyiene.

4. The compound of claim 1 , wherein R⁵ is ~C¾-.

5. The compound of claim 1 to 4, wherein R⁶ is phenyl, piperidyl, C1-C8 alkyi, or C3- C8 eycloalkyl, which phenyl, pipyridyl, alkyi or eycloalkyl is unsubstituted or substituted from 1 to 3 times with sulfono, halo, amino, nitro, alkyi, alkoxyl, haloalkyl, eycloalkyl, heterocycloalkyl, aryl, or heteroaryl

6. The compound of claim 1 to 5, wherein R⁴ is H,

7. The compound of claim 1, wherein said compound has a structure selected from the group consisting of:

UNC2427A

UNC2343A

UNC2340A

UNC2324A

61

UNC3017A

UNC3588A

UNC3040A

and pharmaceutically acceptable salts thereof,

8. A composition comprising a compound of claim 1 to 7 in a pharmaceutically acceptable carrier.

9. A method of treating cancer in a subject in need thereof, comprising administering said subject, a compound of claim 1 to 7 in an amoimt effective to treat said cancer,

10. The method of claim 9, wherein said cancer is selected .from the group consisting of myeloid leukemia, lymphoblastic leukemia, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine, and brain cancer.

1 1. A compound of claim 1 to 7 for use in the treatment of cancer or for the preparation of a. medicament for treating cancer.

12. The use of claim 11, wherein said cancer is selected from the group consisting of myeloid leukemia, lymphoblastic leukemia, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine, and brain cancer.